News Financials About Visit Website Latest News BioCorRx Reports Business Update for the Second Quarter of 2024 BioCorRx Reports Business Update for the First Quarter of 2024 May. 16, 2024 8:30 AM ET BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia Apr. 3, 2024 8:30 AM ET BioCorRx Reports Business Update for 2023 Apr. 2, 2024 8:30 AM ET More News Financials About Contact 714-462-4884 Visit Website BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD Feb. 28, 2024 10:52 AM ET BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors Feb. 8, 2024 9:58 AM ET BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President Jan. 9, 2024 8:30 AM ET BioCorRx Reports Business Update for the Third Quarter of 2023 Nov. 14, 2023 12:54 PM ET BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder Aug. 15, 2023 9:00 AM ET BioCorRx Reports Business Update for the Second Quarter of 2023 Aug. 14, 2023 4:41 PM ET BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder Jul. 18, 2023 8:30 AM ET BioCorRx Provides Business Update for the First Quarter of 2023 May. 16, 2023 8:30 AM ET BioCorRx Provides Business Update for 2022 Apr. 3, 2023 8:30 AM ET BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting Mar. 7, 2023 3:18 PM ET BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data Feb. 23, 2023 8:30 AM ET BioCorRx to Present at Sequire Biotechnology Conference on February 2nd Jan. 27, 2023 8:30 AM ET BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors Jan. 24, 2023 9:00 AM ET BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jan. 19, 2023 8:30 AM ET BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States Dec. 7, 2022 9:00 AM ET BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc. Nov. 22, 2022 9:00 AM ET BioCorRx Provides Business Update for the Third Quarter of 2022 Nov. 15, 2022 9:00 AM ET BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Oct. 13, 2022 8:30 AM ET BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep. 6, 2022 8:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2022 Aug. 16, 2022 8:30 AM ET BioCorRx to Participate in the Benzinga All Access Event on July 15th Jul. 13, 2022 8:30 AM ET BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jun. 30, 2022 9:00 AM ET BioCorRx Featured on LiveNOW from FOX Jun. 17, 2022 9:00 AM ET BioCorRx to Present at the LD Micro Invitational XII on June 7th May. 31, 2022 9:00 AM ET BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting May. 19, 2022 8:00 AM ET BioCorRx Business Update for the First Quarter of 2022 May. 17, 2022 8:30 AM ET BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 27, 2022 8:30 AM ET BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 11, 2022 8:30 AM ET BioCorRx Provides 2021 Year-End Business Update Apr. 1, 2022 8:30 AM ET BioCorRx to Participate in Two Upcoming Conferences Mar. 22, 2022 8:30 AM ET BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder Mar. 16, 2022 9:00 AM ET BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104 Feb. 14, 2022 8:30 AM ET BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference Jan. 5, 2022 9:00 AM ET BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board Dec. 9, 2021 9:00 AM ET BioCorRx to Participate in the Benzinga All Access Event on December 2nd Nov. 24, 2021 8:30 AM ET BioCorRx Acquires Intellectual Property for Drug Delivery Nov. 22, 2021 9:15 AM ET BioCorRx Provides Business Update for the Third Quarter of 2021 Nov. 16, 2021 9:15 AM ET BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant Oct. 7, 2021 8:30 AM ET BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th Sep. 29, 2021 12:19 PM ET BioCorRx Files Patent Application with USPTO for Naltrexone Implant Sep. 22, 2021 8:30 AM ET Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 8, 2021 7:00 AM ET BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 1, 2021 8:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2021 Aug. 16, 2021 8:30 AM ET BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board Jun. 22, 2021 8:30 AM ET BioCorRx Provides Business Update for the First Quarter of 2021 May. 18, 2021 9:00 AM ET BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder May. 10, 2021 8:30 AM ET BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone Apr. 13, 2021 8:00 AM ET BioCorRx Provides 2020 Year-End Business Update Apr. 1, 2021 8:30 AM ET BioCorRx Completes $2.25 Million Private Placement Mar. 2, 2021 9:28 AM ET BioCorRx Appoints Finance Veteran Joseph J. Galligan to the Board of Directors Feb. 24, 2021 8:30 AM ET BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders Jan. 15, 2021 8:30 AM ET BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study Nov. 16, 2020 8:30 AM ET BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans Oct. 13, 2020 8:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2020 Aug. 14, 2020 8:30 AM ET BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic May. 22, 2020 8:30 AM ET BioCorRx Offers Free Access to the UnCraveRx Mobile Platform for Weight Loss Management During COVID-19 Pandemic Apr. 10, 2020 8:30 AM ET BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic Apr. 7, 2020 10:26 AM ET BioCorRx Provides Business Update; Pivotal GLP Study of BICX102 Uninterrupted by COVID-19 Pandemic Mar. 31, 2020 8:30 AM ET BioCorRx Announces Senior Management Promotions Mar. 2, 2020 9:15 AM ET BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 30, 2020 9:39 AM ET BioCorRx Provides 2019 Year-End Business Update Dec. 19, 2019 8:30 AM ET BioCorRxs Subsidiary, BioCorRx Pharmaceuticals Provides Update on Potential Overdose Reversal Drug Candidate VDM-001 Dec. 3, 2019 8:30 AM ET BioCorRx Announces UnCraveRx a Medically-Assisted Weight Loss Program as Sponsor and Exhibitor at the 36th Annual American Society of Metabolic and Bariatric Society Meeting Oct. 30, 2019 8:30 AM ET BioCorRx Announces the Official Launch of UnCraveRx, a Medically-Assisted Weight Loss Management Program Oct. 8, 2019 8:30 AM ET BioCorRx Announces Capital Restructuring and Provides Business Update Oct. 7, 2019 8:30 AM ET BioCorRx's Director Louis Lucido Appeared Today on Yahoo Finance LIVE On the Move Jul. 22, 2019 2:12 PM ET BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App Jul. 22, 2019 8:30 AM ET BioCorRx, Inc. Announces Launch of Pilot Program with Louisiana Department of Corrections for Offenders Suffering with Alcohol and Opioid Use Disorders May. 2, 2019 8:00 AM ET BioCorRx Inc. Unveils New UnCraveRx Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director May. 1, 2019 8:30 AM ET BioCorRx to Present at the Planet MicroCap Showcase 2019 on May 1st in Las Vegas Apr. 30, 2019 9:57 AM ET Joseph J. Galligan Appointed as Senior Advisor to BioCorRx Inc. Apr. 4, 2019 7:30 AM ET BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share Apr. 2, 2019 7:30 AM ET BioCorRx's Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida Mar. 28, 2019 8:00 AM ET BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement Mar. 27, 2019 7:00 AM ET BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019 Mar. 14, 2019 8:00 AM ET BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder Feb. 26, 2019 8:00 AM ET BioCorRx Appoints Two Finance Veterans to the Board of Directors Feb. 25, 2019 8:00 AM ET BioCorRx Announces Formation of Scientific Advisory Board Feb. 19, 2019 10:29 AM ET BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market Jan. 23, 2019 8:00 AM ET BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 22, 2019 7:30 AM ET BioCorRx Provides Business Update for the Third Quarter of 2018 Nov. 14, 2018 8:00 AM ET BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families Oct. 19, 2018 7:30 AM ET BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001 Oct. 9, 2018 8:00 AM ET BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida Oct. 5, 2018 7:30 AM ET BioCorRx Provides BICX102 Grant Update Oct. 2, 2018 7:55 AM ET BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew Sep. 25, 2018 11:21 AM ET BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress Sep. 20, 2018 9:00 AM ET Actor Jeremy Miller Appears on Local ABC News Supporting BioCorRx Recovery Program Sep. 12, 2018 7:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2018 Aug. 15, 2018 8:00 AM ET BioCorRx Provides Update on BICX102 Aug. 7, 2018 7:30 AM ET BioCorRx Raises $1.1 Million at Premium to Market Jun. 6, 2018 7:00 AM ET BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102 May. 22, 2018 7:30 AM ET BioCorRx Provides Business Update for the First Quarter of 2018 May. 21, 2018 7:30 AM ET BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant Apr. 30, 2018 7:00 AM ET BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder Apr. 26, 2018 8:57 AM ET BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair Apr. 13, 2018 8:19 AM ET
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia Apr. 3, 2024 8:30 AM ET
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD Feb. 28, 2024 10:52 AM ET
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors Feb. 8, 2024 9:58 AM ET
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President Jan. 9, 2024 8:30 AM ET
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder Aug. 15, 2023 9:00 AM ET
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder Jul. 18, 2023 8:30 AM ET
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting Mar. 7, 2023 3:18 PM ET
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data Feb. 23, 2023 8:30 AM ET
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors Jan. 24, 2023 9:00 AM ET
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jan. 19, 2023 8:30 AM ET
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States Dec. 7, 2022 9:00 AM ET
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc. Nov. 22, 2022 9:00 AM ET
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Oct. 13, 2022 8:30 AM ET
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep. 6, 2022 8:30 AM ET
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jun. 30, 2022 9:00 AM ET
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting May. 19, 2022 8:00 AM ET
BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 27, 2022 8:30 AM ET
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 11, 2022 8:30 AM ET
BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder Mar. 16, 2022 9:00 AM ET
BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104 Feb. 14, 2022 8:30 AM ET
BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board Dec. 9, 2021 9:00 AM ET
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant Oct. 7, 2021 8:30 AM ET
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 8, 2021 7:00 AM ET
BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 1, 2021 8:30 AM ET
BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder May. 10, 2021 8:30 AM ET
BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone Apr. 13, 2021 8:00 AM ET
BioCorRx Appoints Finance Veteran Joseph J. Galligan to the Board of Directors Feb. 24, 2021 8:30 AM ET
BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders Jan. 15, 2021 8:30 AM ET
BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study Nov. 16, 2020 8:30 AM ET
BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans Oct. 13, 2020 8:30 AM ET
BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic May. 22, 2020 8:30 AM ET
BioCorRx Offers Free Access to the UnCraveRx Mobile Platform for Weight Loss Management During COVID-19 Pandemic Apr. 10, 2020 8:30 AM ET
BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic Apr. 7, 2020 10:26 AM ET
BioCorRx Provides Business Update; Pivotal GLP Study of BICX102 Uninterrupted by COVID-19 Pandemic Mar. 31, 2020 8:30 AM ET
BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 30, 2020 9:39 AM ET
BioCorRxs Subsidiary, BioCorRx Pharmaceuticals Provides Update on Potential Overdose Reversal Drug Candidate VDM-001 Dec. 3, 2019 8:30 AM ET
BioCorRx Announces UnCraveRx a Medically-Assisted Weight Loss Program as Sponsor and Exhibitor at the 36th Annual American Society of Metabolic and Bariatric Society Meeting Oct. 30, 2019 8:30 AM ET
BioCorRx Announces the Official Launch of UnCraveRx, a Medically-Assisted Weight Loss Management Program Oct. 8, 2019 8:30 AM ET
BioCorRx's Director Louis Lucido Appeared Today on Yahoo Finance LIVE On the Move Jul. 22, 2019 2:12 PM ET
BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App Jul. 22, 2019 8:30 AM ET
BioCorRx, Inc. Announces Launch of Pilot Program with Louisiana Department of Corrections for Offenders Suffering with Alcohol and Opioid Use Disorders May. 2, 2019 8:00 AM ET
BioCorRx Inc. Unveils New UnCraveRx Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director May. 1, 2019 8:30 AM ET
BioCorRx to Present at the Planet MicroCap Showcase 2019 on May 1st in Las Vegas Apr. 30, 2019 9:57 AM ET
BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share Apr. 2, 2019 7:30 AM ET
BioCorRx's Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida Mar. 28, 2019 8:00 AM ET
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement Mar. 27, 2019 7:00 AM ET
BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder Feb. 26, 2019 8:00 AM ET
BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market Jan. 23, 2019 8:00 AM ET
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 22, 2019 7:30 AM ET
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families Oct. 19, 2018 7:30 AM ET
BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001 Oct. 9, 2018 8:00 AM ET
BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida Oct. 5, 2018 7:30 AM ET
BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew Sep. 25, 2018 11:21 AM ET
BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress Sep. 20, 2018 9:00 AM ET
Actor Jeremy Miller Appears on Local ABC News Supporting BioCorRx Recovery Program Sep. 12, 2018 7:30 AM ET
BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102 May. 22, 2018 7:30 AM ET
BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant Apr. 30, 2018 7:00 AM ET
BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder Apr. 26, 2018 8:57 AM ET
BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair Apr. 13, 2018 8:19 AM ET